Molbio Diagnostics Q1FY27: Profit up 523% YoY

Key result: sharp turnaround after listing

Molbio Diagnostics Limited reported a strong improvement in Q1FY27 performance for the quarter ended June 30, 2026, with profitability swinging to positive from a loss in the year-ago period. The Board of Directors approved the company’s unaudited standalone and consolidated financial results on September 5, 2026. The update comes soon after Molbio Diagnostics completed its IPO in August 2026. The company said the quarter reflected a significant turnaround, supported by robust revenue growth. Alongside the results, Molbio also scheduled an earnings conference call for September 8, 2026 at 4:00 pm IST to discuss Q1FY27 performance.

Consolidated revenue jumps more than four times

On a consolidated basis, revenue from operations for Q1FY27 stood at ₹408.38 crore, up from ₹99.71 crore in the corresponding quarter. The same dataset also presents total income at ₹411.48 crore for Q1FY27, compared with ₹100.47 crore in the year-ago period, reflecting higher other income as well. The company’s narrative highlighted revenue growth of 309% year-on-year to ₹4,083.76 million, which matches ₹408.38 crore in the quarterly table. Molbio attributed the turnaround to strong operational performance, as reflected in the sharp rise in operating profit and improved margins.

Net profit returns to positive, with two reported profit figures

Molbio Diagnostics reported a return to profitability in Q1FY27 compared with a net loss in Q1FY25. In one disclosure, consolidated net profit attributable to owners of the parent company was stated at ₹58.75 crore, reversing a net loss of ₹23.71 crore in the same period last year. Separately, a key metrics table in the same dataset shows consolidated net profit of ₹52.74 crore for Q1FY27 versus a loss of ₹23.94 crore in Q1FY25. The headline figure also referenced net profit of ₹527.44 million, which equals ₹52.74 crore, implying this is the profit figure being highlighted as “up 523% YoY”.

Standalone performance: revenue near ₹400 crore

Standalone revenue for the quarter was reported at ₹399.38 crore, compared with ₹95.32 crore in Q1FY25. Standalone net profit was stated at ₹56.63 crore for Q1FY27, versus a loss of ₹13.41 crore in Q1FY25. This indicates the profitability turnaround was visible at both the standalone and consolidated levels during the quarter.

EPS improvement and bonus-adjusted comparatives

Earnings per share improved sharply year-on-year. Consolidated basic and diluted EPS were reported at ₹5.21 for Q1FY27, compared with a loss per share of ₹2.10 in Q1FY25. Standalone EPS was ₹5.02, compared with a loss of ₹1.19 per share in the prior-year quarter. The company noted that Q1FY25 comparative figures were retrospectively adjusted for a 4:1 bonus issue allotted in September 2025, which affects per-share comparability across periods.

Other income trend differed between standalone and consolidated

Other income moved in different directions for standalone versus consolidated accounts. Standalone other income declined to ₹1.37 crore from ₹1.48 crore in Q1FY25. In contrast, consolidated other income rose to ₹3.10 crore from ₹0.76 crore, which the dataset describes as more than quadrupling year-on-year. This gap is relevant because consolidated other income can reflect group-level income streams and consolidation effects that are not present in standalone results.

IPO update and change in subsidiary stake

Molbio Diagnostics completed its IPO in August 2026, raising ₹200 crore through a fresh issue, according to the dataset. During the quarter, the company also increased its stake in Prognosys Medical Systems to 70%. These corporate actions provide context for the quarter, given the company’s recent transition to being publicly listed and the ongoing changes in group structure.

Board approval and upcoming earnings conference call

The board meeting to consider and approve Q1FY27 standalone and consolidated results was held on September 5, 2026. Molbio Diagnostics also scheduled an earnings conference call for Tuesday, September 8, 2026 at 4:00 pm IST. The company stated the discussion would focus on Q1FY27 results for the quarter ended June 30, 2026. For investors, the call is a key near-term event to hear management commentary tied to the numbers already released.

Stock snapshot and trading range (as reported)

In the dataset, Molbio Diagnostics was shown at ₹1,160.50, up ₹25.30 (2.23%). The day’s range was listed as a low of ₹1,117.20 and a high of ₹1,177.00, with an open of ₹1,139.90 and previous close of ₹1,135.20. The 52-week low and high were reported at ₹926.35 and ₹1,264.60, respectively. Live volume was shown as 5,94,273 shares, with lower and upper circuit limits at ₹928.40 and ₹1,392.60. The dataset also cited a market capitalisation of ₹13,374 crore.

Financial summary table (₹ crore)

Market impact and what investors will track next

The immediate market relevance is the scale of the year-on-year turnaround: revenue rising from about ₹100 crore to above ₹400 crore and a shift from loss to profit. The mix of reported profit figures in the dataset - ₹58.75 crore as “attributable” profit versus ₹52.74 crore in the summary table - is likely to be a focus point for clarity on the earnings call. Investors may also track how the post-IPO capital raise of ₹200 crore is deployed, and whether the increased 70% stake in Prognosys Medical Systems changes consolidated reporting dynamics in coming quarters.

Conclusion

Molbio Diagnostics’ Q1FY27 results show a sharp improvement in revenue and profitability versus the year-ago quarter, following its August 2026 IPO. The next confirmed catalyst is the earnings conference call scheduled for September 8, 2026 at 4:00 pm IST, where management is expected to discuss Q1FY27 performance and related developments.